Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours

Navoximod (GDC-0919) is a small molecule inhibitor of indoleamine-2,3-dioxygenase 1. This study investigated the safety, tolerability and pharmacokinetics of navoximod alone and in combination with atezolizumab in Japanese patients with advanced solid tumours. This was a phase I, open-label, dose-es...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Invest New Drugs
Main Authors: Ebata, Takahiro, Shimizu, Toshio, Fujiwara, Yutaka, Tamura, Kenji, Kondo, Shunsuke, Iwasa, Satoru, Yonemori, Kan, Shimomura, Akihiko, Kitano, Shigehisa, Koyama, Takafumi, Sato, Natsuko, Nakai, Kiyohiko, Inatani, Michiyasu, Yamamoto, Noboru
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2019
Assuntos:
Phase I Studies
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7066107/
https://ncbi.nlm.nih.gov/pubmed/31124055
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-019-00787-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados